Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study

Author(s): Lihua E. Budde, MD1; Sarit Assouline, MD, MSc2; Laurie H. Sehn, MD3; Stephen J. Schuster, MD4; Sung-Soo Yoon, MD, PhD5; Dok Hyun Yoon, MD, PhD6; Matthew J. Matasar, MD7; Francesc Bosch, MD, PhD8; Won Seog Kim, MD, PhD9; Loretta J. Nastoupil, MD10; Ian W. Flinn, MD, PhD11; Mazyar Shadman, MD, MPH12; Catherine Diefenbach, MD13; Chan Yoon Cheah, MBBS, DMedSc14; Connie Y. Ma, MSc15; Huang Huang, MSc16; Antonia Kwan, MBBS, PhD15; Michael C. Wei, MD, PhD15; Shen Yin, PhD15; Nancy L. Bartlett, MD17
Source: https://doi.org/10.1200/JCO.23.02329

Dr. Anjan Patel's Thoughts

Mosunetuzumab has an impressive response rate and durability of response in heavily pre-treated patients with B-cell NHL. This was presented at our webinar on August 7, 2024 by the cellular therapy team, slides are available upon request. We have this drug available at select sites within our practice so please contact us if you have a patient in mind.

ABSTRACT

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.

Mosunetuzumab is a CD20xCD3 T-cell–engaging bispecific antibody administered as an off-the-shelf, fixed-duration treatment in an outpatient setting. We report an updated analysis of the durability of response, by investigator assessment, after an overall median follow-up of 3.5 years in patients with relapsed/refractory indolent or aggressive B-cell non-Hodgkin lymphoma (iNHL/aNHL) from the dose-escalation stage of a phase I/II study of mosunetuzumab (ClinicalTrials.gov identifier: NCT02500407). Across dose levels, 65.7% of patients with iNHL and 36.4% with aNHL achieved a complete or partial response to mosunetuzumab. Median duration of response (DoR) in patients with iNHL for all responders was 23.2 months (95% CI, 13.8 to not estimable [NE]), but was not reached in complete responders (95% CI, 21.0 to NE). After a median time on study of 38.9 months, no relapses were observed beyond 26 months in complete responders. In patients with aNHL, median DoR for all responders was 7.8 months (95% CI, 4.6 to 22.8). Among 12 complete responders who progressed postmosunetuzumab treatment and were retreated with mosunetuzumab, 83.3% had an objective response and 58.3% achieved a second complete response. Our study reports the longest follow-up using bispecific antibodies in patients with B-cell non-Hodgkin lymphoma and demonstrates that mosunetuzumab can mediate durable remissions with time-limited treatment.

Author Affiliations

1City of Hope National Medical Center, Duarte, CA; 2Jewish General Hospital and McGill University, Montreal, Quebec, Canada; 3BC Cancer Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, British Columbia, Canada; 4Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; 5Seoul National University Hospital, Seoul, South Korea; 6Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; 7Rutgers University, New York, NY; 8University Hospital Vall d’Hebron and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; 9Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; 10MD Anderson Cancer Center, Houston, TX; 11Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; 12Fred Hutchinson Cancer Research Center, Seattle, WA; 13Perlmutter Cancer Center at NYU Langone Health, New York, NY; 14Linear Clinical Research Limited, Nedlands, Australia; 15Genentech, Inc, South San Francisco, CA; 16Hoffmann-La Roche Limited, Mississauga, Ontario, Canada; 17Siteman Cancer Center, Washington University School of Medicine, St Louis, MO

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia

Maybe it’s me, but I find these prognostic/risk stratification tools helpful especially when they are simple. This study shows that LDH, albumin, age of 66-75 all were strongly prognostic. This can be easily applied in the clinic to our patients when advising the risk of the disease and the need for potential therapy. Recall that there is a growing armamentarium of drugs in this disease, as well as clinical trials, within our practice.

Read More »

Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

This gives more credence to the idea of avoiding bendamustine before CAR T therapy. Patients exposed to bendamustine had about a 20% lower overall response rate (ORR), 50% shorter progression-free survival (PFS) and >50% shorter overall survival (OS) compared to those who were bendamustine naive. Although other factors may also play a role here, these seem to be significant differences and should make it clear that one should not use this drug before pursuing CAR T therapy.

Read More »

Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study

There are too many options for DLBCL now with monoclonal antibodies, bispecific and CAR-T therapy, but in frail patients, this might be an option. Tafatistamab with lenalidomide had higher ORR (55vs 50) and CR( 37 vs 27%) but this is comparing different trials, and this trial had mostly elderly pts, I do feel tafatistamab is fairly well tolerated though. But when in doubt this seems to be a fair option.

Read More »